{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:31:26Z","timestamp":1757309486987,"version":"3.41.2"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>AHSCT is the treatment of choice for newly diagnosed patients with transplant-eligible multiple myeloma (MM). However, considerable variability in response to autologous hematopoietic stem cell transplantation (AHSCT) results in only 50% of patients achieving complete response (CR) after AHSCT, which is directly associated with improved progression-free and overall survival (OS). In this study, we aimed to investigate the potential predictive role of selected serum miRNAs in MM patients who underwent AHSCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Serum expression level of 6 miRNAs: miR-221-3p, miR-15b-5p, miR-223-3p, miR-320c, miR-361-3p, and miR-150-5p was evaluated in 51 patients who underwent AHSCT. Blood samples were collected at two time points: before conditioning chemotherapy (T1) and fourteen days after transplant (+14) (T2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All selected miRNAs significantly changed their expression level across the procedure- two were up-regulated after AHSCT: hsa-miR-320c (FC 1.42, p&amp;lt;0.0001) and hsa-miR-361-3p (FC 1.35, p=0.0168); four were down-regulated: hsa-miR-15b-5p (FC 0.53, p&amp;lt;0.0001), hsa-miR-221-3p (FC 0.78, p=0.0004), hsa-miR-223-3p (FC 0.74, p=0.0015) and hsa-miR-150-5p (FC 0.75, p=0.0080). Notably, before AHSCT, hsa-miR-223-3p was down-regulated in International Staging System (ISS) III patients (FC=0.76, p=0.0155), and hsa-miR-320c was up-regulated (FC=1.27, p=0.0470). These differences became non-significant after AHSCT. Eight (15.69%) patients achieved CR before AHSCT and 17 patients (33.33%) at +100 days after AHSCT. In multivariate logistic regression analysis, achievement of CR after induction and hsa-miR-223-3p at T1 were independent predictors of CR after AHSCT. In multivariate Cox regression analysis, hsa-miR-223-3p at T1 expression level was associated with prolonged OS (HR 0.06, 95%CI: 0.00 - 0.99, p=0.0488).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Serum expression of has-miR-223-3p is a predictor of CR and prolonged OS in MM patients undergoing AHSCT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1250355","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T06:02:05Z","timestamp":1695880925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"13","author":[{"given":"Damian","family":"Mikulski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Nowicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Dr\u00f3\u017ad\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Misiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kacper Piotr","family":"Ko\u015bcielny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol","family":"Oko\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Krawiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewelina","family":"Perdas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17888","article-title":"Real-World Data on Survival Improvement in Patients with Multiple Myeloma Treated at a Single Institution over a 45-Year Period","volume":"196","author":"Rodr\u00edguez-Lobato","year":"2022","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204","article-title":"Prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe fran\u00e7ais du my\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"B6","unstructured":"BaldomeroH\n            PasswegJ\n          30 Years EBMT ACTIVITY SURVEY and 2019 annual report"},{"key":"B7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjh.16764","article-title":"The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift","volume":"191","author":"Kazandjian","year":"2020","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000783","article-title":"The role of autologous stem-cell transplantation in multiple myeloma in 2021","volume":"33","author":"Mina","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with Cyclophosphamide and Dexamethasone or Lenalidomide and Dexamethasone plus Autologous Transplantation or Carfilzomib plus Lenalidomide and Dexamethasone, Followed by Maintenance with Carfilzomib plus Lenalidomide or Lenalidomide Alone For","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.180","article-title":"Impact of early relapse after auto-SCT for multiple myeloma","volume":"42","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1673-8527(09)60001-1","article-title":"Small but influential: the role of microRNAs on gene regulatory network and 3\u2019UTR evolution","volume":"36","author":"Zhang","year":"2009","journal-title":"J Genet Genomics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrg2843","article-title":"The widespread regulation of microRNA biogenesis, function and decay","volume":"11","author":"Krol","year":"2010","journal-title":"Nat Rev Genet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular miRNAs: from biomarkers to mediators of physiology and disease","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrg.2016.134","article-title":"Network-biology perspective of microRNA function and dysfunction in cancer","volume":"17","author":"Bracken","year":"2016","journal-title":"Nat Rev Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/985408","article-title":"MicroRNAs expression profiles in cardiovascular diseases","volume":"2014","author":"Bronze-da-Rocha","year":"2014","journal-title":"BioMed Res Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1152\/physiolgenomics.00168.2010","article-title":"MicroRNA in central nervous system trauma and degenerative disorders","volume":"43","author":"Liu","year":"2011","journal-title":"Physiol Genomics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.40","article-title":"MicroRNAs as regulatory elements in immune system logic","volume":"16","author":"Mehta","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1278436","article-title":"MicroRNA as a therapeutic target in cardiac remodeling","volume":"2017","author":"Chen","year":"2017","journal-title":"BioMed Res Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2014.00031","article-title":"MicroRNAs regulate neuronal plasticity and are involved in pain mechanisms","volume":"8","author":"Elramah","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00598-2","article-title":"Exosomal microRNAs may aid differential diagnosis of movement disorders","volume":"18","author":"Wood","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020702","article-title":"Circulating microRNA: the potential novel diagnostic biomarkers to predict drug resistance in temporal lobe epilepsy, a pilot study","volume":"22","author":"De Benedittis","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41582-021-00611-8","article-title":"Exosomal microRNA is promising biomarker in PD","volume":"18","author":"Lempriere","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-020-00291-4","article-title":"Roles of miRNA dysregulation in the pathogenesis of multiple myeloma","volume":"28","author":"Chen","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.2003980","article-title":"Identification of key miRNA signature and pathways involved in multiple myeloma by integrated bioinformatics analysis","volume":"26","author":"Dong","year":"2021","journal-title":"Hematology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2020.191229","article-title":"Circulating microRNAs in multiple myeloma: A literature review","volume":"66","author":"Tiruneh","year":"2020","journal-title":"Clin Lab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2174\/156800912802429274","article-title":"MicroRNAs in the pathobiology of multiple myeloma","volume":"12","author":"Lionetti","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2014.946906","article-title":"The potential of miRNAs as biomarkers for multiple myeloma","volume":"14","author":"Rocci","year":"2014","journal-title":"Expert Rev Mol Diagn"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092569","article-title":"The value of serum microRNA expression signature in predicting refractoriness to bortezomib-based therapy in multiple myeloma patients","volume":"12","author":"Robak","year":"2020","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1182\/blood-2021-152179","article-title":"Changes in the microrna expression profile in patients undergoing autologous steam cell transplantation","volume":"138","author":"Mikulski","year":"2021","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the international myeloma working group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"36","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2015.06.006","article-title":"Aberrant levels of miRNAs in bone marrow microenvironment and peripheral blood of myeloma patients and disease progression","volume":"17","author":"Wang","year":"2015","journal-title":"J Mol Diagn"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.14800\/rd.1529","article-title":"The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma","volume":"4","author":"Alzrigat","year":"2017","journal-title":"RNA Dis (Houston Tex)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0489","article-title":"13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells","volume":"22","author":"Gull\u00e0","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222313144","article-title":"Cancer-related microRNA signature shows biomarker utility in multiple myeloma","volume":"22","author":"Papanota","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4014\/jmb.2010.10059","article-title":"The effect of miR-361-3p targeting TRAF6 on apoptosis of multiple myeloma cells","volume":"31","author":"Fan","year":"2021","journal-title":"J Microbiol Biotechnol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s13258-017-0518-7","article-title":"MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy","volume":"39","author":"Bong","year":"2017","journal-title":"Genes Genomics"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2013\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12859-020-03743-8","article-title":"NormiRazor: tool applying GPU-accelerated computing for determination of internal references in microRNA transcription studies","volume":"21","author":"Grabia","year":"2020","journal-title":"BMC Bioinf"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1101\/2022.06.01.494299","article-title":"OmicSelector: automatic feature selection and deep learning modeling for omic experiments","author":"Stawiski","year":"2022","journal-title":"bioRxiv"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nature06607","article-title":"Regulation of progenitor cell proliferation and granulocyte function by microRNA-223","volume":"451","author":"Johnnidis","year":"2008","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001166","article-title":"Circular RNA circ-CCT3 promotes bortezomib resistance in multiple myeloma via modulating miR-223-3p\/BRD4 axis","volume":"33","author":"Liu","year":"2022","journal-title":"Anticancer Drugs"},{"key":"B52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003857","article-title":"Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma","volume":"5","author":"Parmar","year":"2021","journal-title":"Blood Adv"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.624725","article-title":"Tumor immune microenvironment and its related miRNAs in tumor progression","volume":"12","author":"Xing","year":"2021","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.04.069","article-title":"MiR-320a regulates cell proliferation and apoptosis in multiple myeloma by targeting pre-B-cell leukemia transcription factor 3","volume":"473","author":"Lu","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14378","article-title":"EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions","volume":"8","author":"Alzrigat","year":"2017","journal-title":"Oncotarget"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw116","article-title":"Distribution of miRNA expression across human tissues","volume":"44","author":"Ludwig","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13046-016-0357-4","article-title":"MicroRNA-361-3p suppresses tumor cell proliferation and metastasis by directly targeting SH2B1 in NSCLC","volume":"35","author":"Chen","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.018","article-title":"Correlation of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with susceptibility and prognosis for multiple myeloma","volume":"19","author":"Wu","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2761","article-title":"Serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma","volume":"6","author":"Navarro","year":"2015","journal-title":"Oncotarget"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742296","article-title":"Prognostic role of circulating exosomal miRNAs in multiple myeloma","volume":"129","author":"Manier","year":"2017","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13036","article-title":"MiRNA-15a, miRNA-16, miRNA-126, miRNA-146a, and miRNA-223 expressions in autologous hematopoietic stem cell transplantation and their impact on engraftment","volume":"100","author":"Nowicki","year":"2018","journal-title":"Eur J Haematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6320329","article-title":"Effect of autologous stem cell transplantation combined with modified VTD regimen on elderly patients with multiple myeloma and its influence on miRNA cytokines","volume":"2022","author":"Bai","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0191","article-title":"Impact of miRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"18","author":"de Larrea","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12885-023-10665-0","article-title":"MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation","volume":"23","author":"Rafiee","year":"2023","journal-title":"BMC Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16413","article-title":"Predictive impact of circulating microRNA-193a-5p on early relapse after autologous stem cell transplantation in patients with multiple myeloma","volume":"189","author":"Park","year":"2020","journal-title":"Br J Haematol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03154-2","article-title":"Circulatory miR-155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation, a multivariate analysis","volume":"114","author":"Rafiee","year":"2021","journal-title":"Int J Hematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"key":"B69","unstructured":"ClinicalTrials.govA Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma"},{"volume-title":"ACCESS TO MODERN MEDICAL THERAPIES FOR MULTIPLE Poland vs Europe","year":"2020","author":"Bia\u0142kowska-cybula","key":"B70"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.20452\/PAMW.15980","article-title":"Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a \u201cReal-world\u201d Study: experiences of the Polish myeloma group","volume":"131","author":"Charli\u0144ski","year":"2021","journal-title":"Polish Arch Intern Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1250355\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T06:02:14Z","timestamp":1695880934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1250355\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":71,"alternative-id":["10.3389\/fonc.2023.1250355"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1250355","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"article-number":"1250355"}}